The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) Study

Stuart J. Connolly, Lars Wallentin, Michael D. Ezekowitz, John Eikelboom, Jonas Oldgren, Paul A. Reilly, Martina Brueckmann, Janice Pogue, Marco Alings, John V. Amerena, Alvaro Avezum, Iris Baumgartner, Andrzej J. Budaj, Jyh-Hong Chen, Antonio L. Dans, Harald Darius, Giuseppe Di Pasquale, Jorge Ferreira, Greg C. Flaker, Marcus D. FlatherMaria Grazia Franzosi, Sergey P. Golitsyn, David A. Halon, Hein Heidbuchel, Stefan H. Hohnloser, Kurt Huber, Petr Jansky, Gabriel Kamensky, Matyas Keltai, Sung Soon Kim, Chu-Pak Lau, Jean-Yves Le Heuzey, Basil S. Lewis, Lisheng Liu, John Nanas, Razali Omar, Prem Pais, Knud E. Pedersen, Leopoldo S. Piegas, Dimitar Raev, Pal J. Smith, Mario Talajic, Ru San Tan, Supachai Tanomsup, Lauri Toivonen, Dragos Vinereanu, Denis Xavier, Jun Zhu, Susan Q. Wang, Christine O. Duffy, Ellison Themeles, Salim Yusuf

Research output: Contribution to journalArticlepeer-review

204 Citations (Scopus)


During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses.
Original languageEnglish
Pages (from-to)237-243
Number of pages7
Issue number3
Publication statusPublished - 16 Jul 2013


  • Dose-Response Relationship, Drug
  • Humans
  • Stroke
  • Aged
  • Hemorrhage
  • beta-Alanine
  • Antithrombins
  • Benzimidazoles
  • Hospitalization
  • Aged, 80 and over
  • Embolism
  • Treatment Outcome
  • Middle Aged
  • Follow-Up Studies
  • Atrial Fibrillation
  • Female
  • Male

Cite this